- School leavers
- Entry level
- Graduate Programs
- International Future Leadership Program for Production - Engineers, Pharmacists, Natural Scientists
- Global Trainee Program for Supply Chain Management
- International Trainee Program in Clinical Development
- International Procurement Management Trainee Program
- International Trainee Program Phyto Sourcing
- International Trainee Program for Financial Management
- International Trainee Program in Human Resources Management
- Trainee Program Marketing & Sales at Bayer Vital
- Trainee Program in Marketing, Sales and Development at Crop Science Germany
- Communications traineeship
- Career entry
- Career entry in Inhouse Consulting
- Career entry in IT
- Graduate Programs
- Functional Areas
- Law and Patents
- Brand Management Consumer Health
- Pharmaceutical production
- Finance / Accounting / Controlling
- Information technology
- IT for Research & Development
- Business Consulting
- Digital Marketing
- Meet our Employee
Working together on new therapeutic options for hemophilia
For the benefit of patients: Bayer is expanding manufacturing capacity for its new recombinant Factor VIII (rFVIII) therapies at its sites in Wuppertal and Leverkusen, Germany, to offer innovative treatment options to hemophilia A patients. The company is investing more than €500 million in these projects and needs to staff a variety of challenging positions. This is your chance: join us and help to improve the lives of patients around the world.
Some 400,000 people around the world are affected by hemophilia A. Their blood cannot clot properly due to a deficiency or a defect in coagulation factor VIII (rFVIII). People with this disorder suffer repeated episodes of bleeding into the muscles, joints or other tissues, which can lead to long-term damage. This coagulation factor is manufactured by biotechnological methods using modified cells that produce human factor VIII molecules.
By establishing a second supply source in Germany – in addition to the existing production site in Berkeley, California, United States – we are addressing the growing global demand for hemophilia treatment. As part of this forward-looking investment in our factor VIII manufacturing, filling and packaging, Bayer HealthCare plans to create about 500 new jobs in Wuppertal and Leverkusen by the year 2020.
What are the job profiles for the two sites?
To help us establish these additional production capacities, we are offering you the opportunity to collaborate at modern workplaces in an inspiring and open environment with colleagues who share your passion – the opportunity to turn groundbreaking ideas into solutions that make life better.
At the Wuppertal site we are looking for applicants with biotechnology and cleanroom experience for a number of positions including the following:
- chemical production technicians (mainly shiftwork, plus a limited number of day-shift-only positions)
- chemical and biological laboratory assistants in production and quality assurance for biopharmaceutical production
- production technicians for biopharmaceutical production
- chemical supervisors in a biopharmaceutical environment
At the Leverkusen site we are looking for applicants with biotechnology and cleanroom experience for a number of positions including the following:
- pharmaceutical production technicians for biopharmaceutical production or people with experience in aseptic production
- engineers, technicians and skilled manual workers for biopharmaceutical production
At both sites you have also the option to enter Bayer through a scientific vocational training program. Find out more. Open positions in our training programs can be found via the direct links to job openings at our Wuppertal and Leverkusen sites in the next paragraph.
If you’re interested in any of these positions we look forward to receiving your application, which you can submit directly via our online vacancy notices.
Please note that not all the positions listed are directly associated with the expansion of production for hemophilia treatments. Further vacancies in related areas may also be included.
More about hemophilia
You may get more information about hemophilia and patient's lifes in the spring edition of the Bayer magazine. The top story tells us of Lu from China, who suffers from the disorder. A doctor at Beijing Children’s Hospital gave his parents hope, because with the aid of medication, the 11-year-old is now able to live an almost normal life. Read more!
Bayer has launched a new recruiting system that makes it faster and easier for you to apply. Therefore we have two Login-possibilities: